“As the face of neighborhood healthcare, community pharmacies have contributed mightily to the progress that the IMS Health report has found in the areas of improved medication adherence and the use of generic drugs. By identifying $200 billion per year in avoidable costs, the report serves as an invitation for policymakers, private payers, employers, the entire healthcare delivery system, and patients to better leverage the value of community pharmacy to improve health and healthcare affordability.
“Though perhaps best known for their important role in helping patients use medicines safely and stay healthy, innovative pharmacy services do even more. From vaccinations, to health education, to disease state testing and management, personal and face-to-face interactions with community pharmacists go a long way to advance preventive care. While pharmacists are widely trusted and accessible, they are particularly valued by those in the greatest need.
“NACDS will work to ensure that this report, and other aspects of the mounting evidence in support of community pharmacy services to address pressing health needs, fuels additional support for the Medication Therapy Management Empowerment Act – S. 557 in the Senate and H.R. 1024 in the House of Representatives.”
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs